Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.50 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326237 | 1.00 | PDE5A (0.63) | PDE5ABCHEACHEABCG2ABCB1 | |
| SCHEMBL1327014 | 0.95 | PDE5A (0.69) | PDE5ABCHEACHE | |
| SCHEMBL1327573 | 0.94 | PDE5A (0.69) | PDE5ABCHEACHEABCG2ABCB1 | |
| SCHEMBL1327294 | 0.92 | PDE5A (0.61) | PDE5ABCHEACHEABCG2ABCB1 | |
| SCHEMBL1327291 | 0.92 | PDE5A (0.61) | PDE5ABCHEACHEABCG2ABCB1 | |
| SCHEMBL1326798 | 0.89 | PDE5A (0.77) | PDE5A | |
| SCHEMBL1327016 | 0.89 | PDE5A (0.77) | PDE5A | |
| SCHEMBL1327104 | 0.89 | PDE5A (0.77) | PDE5A | |
| SCHEMBL1327034 | 0.88 | PDE5A (0.66) | PDE5ABCHEACHE | |
| SCHEMBL1326360 | 0.88 | PDE5A (0.69) | PDE5ABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | claimed |
| US-8058305-B2 | Pyrrolidine derivatives as prostaglandin modulators | MERCK SERONO SA (CH) | 2011-11-15 | — | — | US | disclosed |
| EP-1458679-B1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | MERCK SERONO SA (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-7635713-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2009-12-22 | — | — | US | disclosed |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2009-11-26 | — | — | US | disclosed |
| EP-1331950-B1 | EX VIVO METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-15 | — | — | US | disclosed |
| US-7335680-B2 | Pyrrolidine derivatives as prostaglandin modulators | LABORATOIRES SERONO SA (CH) | 2008-02-26 | — | — | US | disclosed |
| US-6992070-B2 | Methods and compositions for nucleic acid delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| WO-2002030470-A9 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | UNIV JOHNS HOPKINS (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | disclosed |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | JOHNS HOPKINS UNIVERSITY | 2002-07-18 | — | — | US | disclosed |
| WO-2002030470-A1 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | JOHNS HOPKINS UNIVERSITY (US) | 2002-04-18 | — | — | WO | disclosed |
| EP-0912567-B1 | CARBOLINE DERIVATIVES | ICOS CORP (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6306870-B1 | PHOSPHODIESTERASE ENZYME INHIBITORS, CARDIOVASCULAR DISORDERS AND SEXUAL DISORDERS | ICOS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| US-6117881-A | POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE | ICOS CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0912567-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043287-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128171-A1 | Methods for prevention and treatment of gastrointestinal disorders | VIP, GIPR, IAPP | PDE5A 302/4885BCHE 410/4885ACHE 55/4885 |
| US-20090292000-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | PDE5A 3/4885BCHE 2040/4885ACHE 885/4885 |
| US-20020094326-A1 | Methods and compositions for nucleic acid delivery | TNNC1, TNNI3, TNNT2 | PDE5A 2130/4885BCHE 4586/4885ACHE 4875/4885 |
| US-20050176800-A1 | Pyrrolidine derivatives as prostaglandin modulators | PGF, PTGIS, PTGIR | PDE5A 9/4885BCHE 2520/4885ACHE 1466/4885 |
| US-20080114051-A1 | PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS | PGF, PTGIS, PDE5A | PDE5A 3/4885BCHE 2040/4885ACHE 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.